(MT Newswires) Stéphane Bancel, CEO of Moderna, announces a significant breakthrough for cancer patients, particularly those suffering from melanoma. Moderna uses its technology to develop personalized treatments, where each patient receives a specific drug tailored to the DNA of his or her cancer cells. Data show that the drug developed by Moderna, compared with the best treatment currently available, Merck's Keytruda, improved progression-free survival by 44% after two years, and this improvement reached 49% after three years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
151 USD | -2.38% | +5.93% | +51.85% |
Jun. 08 | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |
Jun. 07 | Moderna Files With FDA for Updated Covid Shot | DJ |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
151 USD | -2.38% | +5.93% | 57.87B | ||
130.7 USD | +0.11% | +4.09% | 331B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B | |
-9.14% | 11.06B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Stéphane Bancel, CEO of Moderna: Merck-Moderna vaccine reduces risk of skin cancer recurrence